Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Julphar
Farmers Insurance
Queensland Health
QuintilesIMS
McKinsey
Boehringer Ingelheim
Cerilliant
Deloitte

Generated: April 21, 2018

DrugPatentWatch Database Preview

DIPENTUM Drug Profile

« Back to Dashboard

When do Dipentum patents expire, and what generic alternatives are available?

Dipentum is a drug marketed by Mylan Speciality Lp and is included in one NDA.

The generic ingredient in DIPENTUM is olsalazine sodium. There are five drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the olsalazine sodium profile page.
Drug patent expirations by year for DIPENTUM
Pharmacology for DIPENTUM
Ingredient-typeAminosalicylic Acids
Drug ClassAminosalicylate
Synonyms for DIPENTUM
(E)-5,5'-(diazene-1,2-diyl)bis(2-hydroxybenzoic acid)
1004301-38-5
3,3'-(E)-diazene-1,2-diylbis(6-hydroxybenzoic acid)
5-[(2E)-2-(3-carboxy-4-oxocyclohexa-2,5-dien-1-ylidene)hydrazinyl]-2-hydroxybenzoic acid
5-[(E)-2-(3-carboxy-4-hydroxyphenyl)diazen-1-yl]-2-hydroxybenzoic acid
5,5'-azodisalicylic acid
6054-98-4
AB0106111
AC1NSEDP
AC1NUWCP
AKOS015896356
AKOS025286102
AS-15939
Azodisal
Azodisal disodium
azodisal sodium
azodisalicylate
C.I. 14130
CCG-213070
CHEMBL1201013
CHEMBL425
CJ 91B
CJ-91B
CS-2050
D00KRE
di-5-ASA
Di-mesalazine
disodium 5-[(2E)-2-(3-carboxylato-4-oxocyclohexa-2,5-dien-1-ylidene)hydrazinyl]-2-hydroxybenzoate
disodium;5-[(E)-(3-carboxylato-4-hydroxyphenyl)diazenyl]-2-hydroxybenzoate
DR001219
HMS3264H09
HY-B0174
I06-1888
MFCD00013300
MolPort-044-559-777
Olsalazine
Olsalazine (Disodium)
Olsalazine Disodium
Olsalazine disodium salt
OLSALAZINE SODIUM
OR226217
SC-47085
SCHEMBL25118
SCHEMBL2628413
SCHEMBL29767
Sodium azodisalicylate
ST24048843
ST51053274
ULS5I8J03O
UNII-ULS5I8J03O
UNII-Y7JEW0XG7I
Y7JEW0XG7I
ZINC12503280

US Patents and Regulatory Information for DIPENTUM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan Speciality Lp DIPENTUM olsalazine sodium CAPSULE;ORAL 019715-001 Jul 31, 1990 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
AstraZeneca
Citi
Cipla
McKesson
Federal Trade Commission
US Department of Justice
Boehringer Ingelheim
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.